Prognostic value of complete metabolic response on 18F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer
Open Access
- 1 January 2022
- journal article
- research article
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 33 (3) , e28
Abstract
Chung YS, et al. J Gynecol Oncol. 2022 Jan;33(3):e28. https://doi.org/10.3802/jgo.2022.33.e28Keywords
Funding Information
- Shin Poong Pharm. Co. Ltd.
This publication has 28 references indexed in Scilit:
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancerGynecologic Oncology, 2013
- Metabolic Response of Rectal Cancer Assessed by 18-FDG PET Following Chemoradiotherapy is Prognostic for Patient OutcomeDiseases of the Colon & Rectum, 2011
- Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?Journal of Gynecologic Oncology, 2011
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Prediction of Tumor Response to Neoadjuvant Therapy in Patients with Esophageal Cancer with Use of18F FDG PET: A Systematic ReviewRadiology, 2010
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinomaAmerican Journal of Obstetrics and Gynecology, 2008
- Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced-Stage Ovarian CancerJournal of Clinical Oncology, 2005